Skip to Content Facebook Feature Image

Hong Kong International Healthcare Week Returns in May: Asia Summit on Global Health and Medical Fair to Drive MedTech & Investment

HK

Hong Kong International Healthcare Week Returns in May: Asia Summit on Global Health and Medical Fair to Drive MedTech & Investment
HK

HK

Hong Kong International Healthcare Week Returns in May: Asia Summit on Global Health and Medical Fair to Drive MedTech & Investment

2026-04-29 17:50 Last Updated At:04-30 10:27

The fifth edition of the International Healthcare Week, organised by the Hong Kong Trade Development Council (HKTDC), will be held in Hong Kong from 11 to 31 May. The two flagship events – the sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the Hong Kong Special Administrative Region and the HKTDC, and the 17th Hong Kong International Medical and Healthcare Fair (Medical Fair), organised by the HKTDC and co-organised by the Hong Kong MedTech Association – serve as a comprehensive business platform covering the entire medical and healthcare industry chain, including technology R&D, investment matching, medical equipment manufacturing, medical products and services. The events will be held concurrently to maximise synergy at the Hong Kong Convention and Exhibition Centre in Wan Chai next month. The ASGH will take place on 11 and 12 May, while the Medical Fair will run from 11 to 13 May.

Sophia Chong, Executive Director of the HKTDC, said: “The medical and healthcare landscape is undergoing a profound and rapid transformation. Hong Kong, by leveraging its preeminence as an international financial centre, its world-class research ecosystem and its unique positioning bridging the Chinese Mainland and the world, serves as an ideal platform for scientific excellence, strategic investment and financing, and international trade for medical and healthcare innovation. The National 15th Five-Year Plan prioritises health development. The HKTDC will actively align with the Plan through the two flagship events of the International Healthcare Week – the ASGH and the Medical Fair. The events will focus on high-growth areas such as biopharmaceuticals, AI-empowered healthcare, the silver economy and modernisation of traditional Chinese medicine, and will help to accelerate commercialisation of research outcome, facilitate high-impact business matching, and boost cross-border investment. Collectively, the twin events reinforce the ‘Healthy China’ initiative, solidify Hong Kong’s position as Asia’s leading biotech and investment hub, and demonstrate Hong Kong’s role as a superconnector and super value-adder.”

More Images
Last year's Asia Summit on Global Health highlights

Last year's Asia Summit on Global Health highlights

Prof Michael Levitt, Nobel Laureate in Chemistry

Prof Michael Levitt, Nobel Laureate in Chemistry

Deal-making sessions at the Asia Summit on Global Health

Deal-making sessions at the Asia Summit on Global Health

Previous edition of the Medical Fair exhibition hall

Previous edition of the Medical Fair exhibition hall

Collaborative innovation and academic research in medical sector

Collaborative innovation and academic research in medical sector

Artificial intelligence and robotics in healthcare demonstration

Artificial intelligence and robotics in healthcare demonstration

Speaker line-up features Nobel Prize Laureate

The sixth ASGH, themed “Fuelling Healthcare Breakthroughs”, will convene a prestigious assembly of international health officials, scientific, medical and industry experts, start-ups and investors. Through various sessions, they will exchange valuable insights and navigate the latest frontiers in public health, medtech, international trade and investment, while unlocking the future prospects and untapped business opportunities of the industry.

The opening session will feature welcome remarks by Prof Frederick S Ma, Chairman of the HKTDC, and opening remarks by John Lee, the Chief Executive of the Hong Kong Special Administrative Region, followed by special remarks of Prof Zeng Yixin, Vice Minister of the National Health Commission.

On the morning of the first day, two plenary sessions will be held. Plenary Session I: Strengthening Pandemic Preparedness through Global Collaboration will begin with a keynote speech by Prof Lo Chung-mau, Secretary of Health of the HKSAR government. The session will be moderated by Prof Leo Poon, Daniel CK Yu Professor in Virology at the School of Public Health of the University of Hong Kong and Co-Director of The Hong Kong Jockey Club Global Health Institute. Speakers include Prof Ibrahim Abubakar, Vice-Provost (Health) at University College London; Dr Leung Yiu-hong, Head of Emergency Response and Programme Management Branch, Department of Health; Dr Kumanan Rasanathan, Executive Director of the WHO Alliance for Health Policy and Systems Research; Prof Wang Yu, Chairman, Chinese Foundation for Hepatitis Prevention and Control; and Dr In Kyu Yoon, Acting Deputy Director General at the International Vaccine Institute. They will delve into critical strategies such as pathogen surveillance, data sharing, and multinational collaboration to bolster the resilience of global health infrastructure.

Plenary Session II: Fuelling Healthcare Breakthroughs will examine how cross-sector collaboration catalyses the commercialisation of research outcomes and unlocks market potential. The session will feature a special address by Leng Weiqing, Chairman of Shanghai Industrial Investment (Holdings). It will be moderated by Victor Chu, Chairman and CEO of First Eastern Investment Group, with speakers including Jonathan Symonds, Chairman of GSK; Prof Song Ruilin, President of the China Pharmaceutical Innovation and Research Development Association; Dr Mehmood Khan, CEO of The Hevolution Foundation; Clara Chan, CEO of Hong Kong Investment Corporation Limited; David Lau of JP Morgan Securities; and Theresa Tse, Chairwoman of Sino Biopharmaceutical Limited.

On the afternoon of the first day, the Dialogue with Global Pioneer in Health session will feature 2013 Nobel Prize Laureate in Chemistry, Prof Michael Levitt, Robert W and Vivian K Cahill Professor in Cancer Research at Stanford University. Prof Levitt will share his distinguished journey in scientific discovery and envision the transformative impact of technology on future healthcare and scientific research.

With rapid advances in AI drug discovery, oncology, and precision medicine, the summit introduces a dedicated CSO Insights: Catalysing Scientific Breakthroughs and Investments for Future Health session on the morning of the second day. Chief Scientific Officers and R&D leaders from leading biotech and pharmaceutical companies, including Fosun Pharma, Omico, Zhaoke Ophthalmology, and more, will share how they set scientific strategy and forge partnerships that accelerate time-to-impact.

Thematic sessions address market trends and the National 15th Five-Year Plan

The pervasive adoption of AI is driving a paradigm shift across industries, including healthcare. This year’s summit will feature two thematic sessions, including Intelligence at Scale: How AI is Powering Real-World Healthcare Revolution and Transforming Healthcare through Digital Health & AI Innovations. Speakers will examine pragmatic integration and pioneering breakthroughs of AI within the healthcare system.

The silver economy represents a high-growth frontier. This year’s Summit will once again feature a dedicated Silver Health Chapter to address the complexities of an ageing demographic and unlock the sector’s burgeoning market potential. In the session Unlocking Growth in Silver Health: From Precision Medicine to Smart Ageing Innovations, distinguished speakers will discuss breakthroughs in the prevention, diagnosis and treatment of age-related diseases.

In response to the National 15th Five-Year Plan, and to catalyse the Healthy China initiative and regional collaboration, the Summit will include a session titled The Next Frontier in China's Healthcare Industry which will review the latest trends in medical innovation and investment in China.

The session Driving Chinese Medicine Development Through Standardisation and Innovation will address the National 15th Five-Year Plan’s emphasis on the inheritance and innovation of traditional Chinese medicine. Speakers will share insight on traditional Chinese medicine innovation, cross-sector collaboration and regulatory matters.

Over the two days, the Summit will cover a wide range of topical issues in the medical and healthcare sector, including sustainable healthcare systems, gene and cell therapy, rare disease treatments, medical robotics and devices, and IP financing strategies for pharmaceuticals and medtech.

Supporting the expansion needs of medical/healthcare enterprises

In addition to the plenary and thematic sessions, the Summit will feature the ASGH Business Hub and InnoHealth Showcase, which presents innovative technologies from some 180 medical and healthcare companies across 11 countries and regions. Many of the exhibitors have received prestigious awards. The Project Pitching session will provide start-ups with the opportunity to present their innovations to potential investors, while the ASGH Deal-making facilitates one-to-one meetings, both online and offline, to channel capital to healthcare projects.

Medical and healthcare enterprises can also access the “GoGlobal Connect” Zone and Business of Healthcare Advisory Zone to consult with service providers on overseas expansion, fundraising, and R&D collaboration. The Summit will also host a workshop titled Hong Kong as a SuperConnector to Empower Global Expansion of Pharmaceutical Enterprises, where medical and business leaders will share how pharmaceutical companies can leverage Hong Kong’s platform to seize overseas business opportunities.

The Medical Fair’s three key categories: MedTech, GeronTech & Preventive Healthcare

The 17th Hong Kong International Medical and Healthcare Fair will be held from 11 to 13 May. Themed Innovations Boosting Smart Health Experience, the Fair will provide an ideal platform for research and development institutions, manufacturers, public healthcare organisations, and healthcare professionals from around the world to establish global business connections.

The Medical Fair will gather some 300 exhibitors from 10 countries and regions. The exhibition will feature seven major zones, including the Startup Zone, Hospital Equipment and Digital Health, Biotechnology and Lab Diagnostics, Laboratory Technologies and Healthcare Services, Medical Supplies and Disposables, Rehabilitation and Elderly Care, and the World of Health and Wellness.

The Fair will focus on three key areas: MedTech, GeronTech and Preventive Healthcare. Among the highlights, an exhibitor will introduce a smart health wearable watch that integrates concepts from both Chinese and Western medicine to assess the functions of the five major internal organs and provide personalized health recommendations.

Another exhibitor will demonstrate an augmented reality (AR) surgical platform designed for orthopaedic surgeons, providing real-time 3D navigation during surgical procedures. In addition, an exhibitor will present a world-first smart knee brace that integrates AI and wearable technology to support post-knee surgery recovery and sports injury rehabilitation.

The Medical Fair actively promotes collaborative innovation across government, industry, academia, research, and investment. A number of leading research and academic institutions will participate, including nine local universities and over 30 innovation and technology enterprises led by Hong Kong Science and Technology Parks.

A startup will showcase innovative voice assistive technology products featuring a one-touch speech reconstruction function. More than 50 themed forums and seminars will be held during the fair, including “Accelerating Mental Health Innovation through AI Research and Adoption” and the “HKMTA Medical Fair Forum 2026: The Medtech Solutions - Greater Bay Area & Overseas”.

The exhibition will continue to adopt the “EXHIBITION+” hybrid model. The physical fair will take place from 11 to 13 May at the HKCEC. Global exhibitors and buyers can engage in discussions via the “Click2Match” smart business matching platform from 4 May until 20 May.

As the two flagship events of International Healthcare Week, the Asia Summit on Global Health and the Hong Kong International Medical and Healthcare Fair will gather global healthcare forces to create a cross-sector exchange platform, driving Hong Kong's development as a regional medical innovation hub.

The Asia Summit on Global Health

Date 11-12 May 2026 (Monday to Tuesday)
9:00am to 6:00pm (Opening Session at 10:00 am on 11 May)

Venue Hong Kong Convention and Exhibition Centre (HKCEC) Hall 3FG

Hong Kong International Medical and Healthcare Fair

Date 11-12 May 2026: 10:00am to 6:00pm
13 May 2026: 10:00am to 5:00pm

Venue Hong Kong Convention and Exhibition Centre (HKCEC) Hall 3DE

Last year's Asia Summit on Global Health highlights

Last year's Asia Summit on Global Health highlights

Prof Michael Levitt, Nobel Laureate in Chemistry

Prof Michael Levitt, Nobel Laureate in Chemistry

Deal-making sessions at the Asia Summit on Global Health

Deal-making sessions at the Asia Summit on Global Health

Previous edition of the Medical Fair exhibition hall

Previous edition of the Medical Fair exhibition hall

Collaborative innovation and academic research in medical sector

Collaborative innovation and academic research in medical sector

Artificial intelligence and robotics in healthcare demonstration

Artificial intelligence and robotics in healthcare demonstration

Hong Kong Science and Technology Parks Corporation (HKSTP),in collaboration with InvestHK as co-organiser, the Hong Kong Trade Development Council (HKTDC) as supporting organisation, and five renowned local universities - The University of Hong Kong, The Chinese University of Hong Kong, The Hong Kong University of Science and Technology, The Hong Kong Polytechnic University and City University of Hong Kong - to form the city’s largest-ever delegation of life and health technology innovators to the BIO International Convention 2026 (BIO 2026) in San Diego, from June 22 to 25.

HKSTP CEO Terry Wong (6th from left back row in photo 6 and 4th from right in photo 7) and five Hong Kong university delegates visited the Salk Institute, home to six Nobel Laureates during BIO 2026 to explore partnerships and shape global biotech momentum through collaborative platforms.

HKSTP CEO Terry Wong (6th from left back row in photo 6 and 4th from right in photo 7) and five Hong Kong university delegates visited the Salk Institute, home to six Nobel Laureates during BIO 2026 to explore partnerships and shape global biotech momentum through collaborative platforms.

HKSTP CEO Terry Wong (6th from left back row in photo 6 and 4th from right in photo 7) and five Hong Kong university delegates visited the Salk Institute, home to six Nobel Laureates during BIO 2026 to explore partnerships and shape global biotech momentum through collaborative platforms.

HKSTP CEO Terry Wong (6th from left back row in photo 6 and 4th from right in photo 7) and five Hong Kong university delegates visited the Salk Institute, home to six Nobel Laureates during BIO 2026 to explore partnerships and shape global biotech momentum through collaborative platforms.

Building on last year’s momentum, the 2026 Hong Kong delegation doubled the size of the Hong Kong Pavilion, expanding to a record of 41 organisations from HKSTP, including partner companies, research institutes, and for the first time with top five universities spin-offs. This landmark presence showcased Hong Kong’s deep strength across AI-enabled biotech, therapeutics, diagnostics, and pharma innovation, with potential outstanding "First-in-Class" and "Best-in-Class" assets. The delegation underscores the city’s leading role as Asia’s largest and the world’s second largest fundraising hub for the biotechnology sector.

In collaboration with InvestHK and HKTDC, HKSTP led a delegation of 41 park companies,institutes and spin-offs from five renowned local universities to showcase the Hong Kong’s life and health technology innovations at BIO 2026 in San Diego.

In collaboration with InvestHK and HKTDC, HKSTP led a delegation of 41 park companies,institutes and spin-offs from five renowned local universities to showcase the Hong Kong’s life and health technology innovations at BIO 2026 in San Diego.

IIn collaboration with InvestHK and HKTDC, HKSTP led a delegation of 41 park companies,institutes and spin-offs from five renowned local universities to showcase the Hong Kong’s life and health technology innovations at BIO 2026 in San Diego.

IIn collaboration with InvestHK and HKTDC, HKSTP led a delegation of 41 park companies,institutes and spin-offs from five renowned local universities to showcase the Hong Kong’s life and health technology innovations at BIO 2026 in San Diego.

Mr. Terry Wong, CEO of HKSTP, said, “BIO 2026 is a premier platform to showcase Hong Kong’s groundbreaking innovation, deepen partnerships, and open new pathways into global healthcare markets. As a super-connector, Hong Kong is uniquely positioned to bridge global innovators with opportunities across Asia and beyond. With strong R&D capabilities backed by world-class universities—five ranked among the QS Top 100, including two with medical schools now placed in the global top 20—Hong Kong’s biotech and medical research excellence is increasingly recognised worldwide. As the city’s innovation ecosystem orchestrator, HKSTP brings together talent, capital, research institutions, clinical partners, and industry leaders to accelerate the journey from discovery to impact. We will continue to empower life and health technology ventures, translating innovation breakthroughs into life-changing solutions that benefit communities around the world.”

Terry Wong, CEO of HKSTP (3rd from right), introduced Hong Kong’s vibrant life and health technology ecosystem to local partners and investors at the fireside chat moderated by Director of HKETO, D.C. Cheung (2nd from right) during the “Bio Nexus HK: From Showcase to Partnership” event organised by the Hong Kong Economic and Trade Office in San Francisco (HKETO San Francisco) and HKTDC. Other speakers included: Joe Panetta, President Emeritus of Biocom (3rd from left); Andy Wong, Head of Innovation & Technology and Life & Health Sciences of InvestHK (2nd from left); Byron Lee, Associate Director, Service Promotion of HKTDC (1st from right); and Lucas Coleman, Director of World Trade Center San Diego (1st from left).

Terry Wong, CEO of HKSTP (3rd from right), introduced Hong Kong’s vibrant life and health technology ecosystem to local partners and investors at the fireside chat moderated by Director of HKETO, D.C. Cheung (2nd from right) during the “Bio Nexus HK: From Showcase to Partnership” event organised by the Hong Kong Economic and Trade Office in San Francisco (HKETO San Francisco) and HKTDC. Other speakers included: Joe Panetta, President Emeritus of Biocom (3rd from left); Andy Wong, Head of Innovation & Technology and Life & Health Sciences of InvestHK (2nd from left); Byron Lee, Associate Director, Service Promotion of HKTDC (1st from right); and Lucas Coleman, Director of World Trade Center San Diego (1st from left).

Terry Wong, CEO of HKSTP (3rd from right), introduced Hong Kong’s vibrant life and health technology ecosystem to local partners and investors at the fireside chat moderated by Director of HKETO, D.C. Cheung (2nd from right) during the “Bio Nexus HK: From Showcase to Partnership” event organised by the Hong Kong Economic and Trade Office in San Francisco (HKETO San Francisco) and HKTDC. Other speakers included: Joe Panetta, President Emeritus of Biocom (3rd from left); Andy Wong, Head of Innovation & Technology and Life & Health Sciences of InvestHK (2nd from left); Byron Lee, Associate Director, Service Promotion of HKTDC (1st from right); and Lucas Coleman, Director of World Trade Center San Diego (1st from left).

Terry Wong, CEO of HKSTP (3rd from right), introduced Hong Kong’s vibrant life and health technology ecosystem to local partners and investors at the fireside chat moderated by Director of HKETO, D.C. Cheung (2nd from right) during the “Bio Nexus HK: From Showcase to Partnership” event organised by the Hong Kong Economic and Trade Office in San Francisco (HKETO San Francisco) and HKTDC. Other speakers included: Joe Panetta, President Emeritus of Biocom (3rd from left); Andy Wong, Head of Innovation & Technology and Life & Health Sciences of InvestHK (2nd from left); Byron Lee, Associate Director, Service Promotion of HKTDC (1st from right); and Lucas Coleman, Director of World Trade Center San Diego (1st from left).

HKSTP and Park Companies Advanced in Cross-border Innovation and Market Expansion

A key highlight of BIO 2026 is witnessing the signing of three major strategic partnerships:

• LabCentral -- HKSTP signed an MOU with one of the largest global non-profit biotech incubators, supporting life sciences startups with high-impact lab infrastructure and scientific community programmes. The collaboration will deepen ties between the U.S. and Hong Kong life sciences ecosystems through startup support, ecosystem engagement, and co-developed programmes, events and strategic initiatives. It will also help connect startups, investors, corporate partners and research institutions, creating stronger pathways for cross-border innovation and commercialisation.

HKSTP and LabCentral signed an MoU at BIO 2026 to strengthen ties and foster cross-border collaboration in life sciences ecosystem in both regions.

HKSTP and LabCentral signed an MoU at BIO 2026 to strengthen ties and foster cross-border collaboration in life sciences ecosystem in both regions.

• Immuno Cure – the developer of the first-in-human novel therapeutic HIV vaccine ICVAX – announced its collaboration with OPIS, an international Contract Research Organization (CRO), at BIO 2026. Leveraging OPIS's full-service, multi-country clinical trial expertise and regulatory knowledge, the partnership will support overseas clinical trial execution and establish a global framework to prepare for international expansion.

Immuno Cure – the developer of the first-in-human novel therapeutic HIV vaccine ICVAX –announced its collaboration with OPIS, an international Contract Research Organization (CRO), at BIO 2026

Immuno Cure – the developer of the first-in-human novel therapeutic HIV vaccine ICVAX –announced its collaboration with OPIS, an international Contract Research Organization (CRO), at BIO 2026

• Zhaoke Ophthalmology signed an MOU with Laboratório Teuto, the first company to produce generic medicines and OTCs (Over the Counter – Prescription Exempt Medicines) in Brazil, to explore cross-border cooperation in ophthalmology. This is Zhaoke's first strategic MOU in Brazil market. Leveraging its innovative pipeline and Teuto's commercial network in Brazil, the partnership aims to bring advanced eye care treatments to Latin American patients while demonstrating the globalisation of Hong Kong-born biotech innovation.

Zhaoke Ophthalmology signed an MOU with Laboratório Teuto to explore cross-border cooperation in ophthalmology.

Zhaoke Ophthalmology signed an MOU with Laboratório Teuto to explore cross-border cooperation in ophthalmology.

Beyond the BIO 2026 Hong Kong Pavilion, HKSTP CEO Mr Terry Wong attended the "Translating Innovation Across Borders: Creating Global Gateways for Biotech Startups" panel sharing session. Mr. Wong shared his insights on cutting-edge biotech trends, Hong Kong’s strengths on life and health tech development, and HKSTP’s role in building a global bridge for nurturing global startup expansion, sustainable innovation and collaboration.

HKSTP CEO Mr Terry Wong (1st from right) attended the "Translating Innovation Across Borders: Creating Global Gateways for Biotech Startups" panel sharing session at BIO 2026.

HKSTP CEO Mr Terry Wong (1st from right) attended the "Translating Innovation Across Borders: Creating Global Gateways for Biotech Startups" panel sharing session at BIO 2026.

Furthermore, HKSTP and five Hong Kong university delegates visited the Salk Institute, home to six Nobel Laureates during BIO 2026 to explore partnerships and shape global biotech momentum through collaborative platforms. HKSTP, in collaboration with InvestHK as co-organiser, HKTDC as the supporting organisation, and powered by the Hong Kong Economic and Trade Office in San Francisco, hosted a Global Mixer during the exhibition. Industry leaders, incubators, and venture capital firms – including Bayer Pharmaceuticals, Johnson & Johnson Innovation, LabCentral, Roche, Simcere Pharmaceutical, and T.Rx Capital – were invited to join the judging panel for startup pitching sessions. The Pavilion also featured executive sharing and curated networking events for commercialisation, licensing, partnerships, investment and international market expansion.

Industry leaders, incubators, and venture capital firms – including Bayer Pharmaceuticals, Johnson & Johnson Innovation, LabCentral, Roche, Simcere Pharmaceutical, and T.Rx Capital – were invited to join the judging panel for startup pitching sessions.

Industry leaders, incubators, and venture capital firms – including Bayer Pharmaceuticals, Johnson & Johnson Innovation, LabCentral, Roche, Simcere Pharmaceutical, and T.Rx Capital – were invited to join the judging panel for startup pitching sessions.

Global recognition at Biomedical Pitch Competition

In the lead-up to BIO 2026, HKSTP actively drove engagement across the biotech sector and co-organised the 2026 Biomedical Pitch Competition with the Boston Capital Investment Club in Boston on May 23 and 24. Competing against around 170 biotechnology companies worldwide, HKSTP park company Meta Pharmaceuticals (HK) Limited won Third Place for its next-generation autoimmune therapeutics. The recognition underscores the strength of Hong Kong’s biotech pipeline and HKSTP’s commitment to translational medicine, commercialisation and globally scalable healthcare solutions.

HK’s biotech ecosystem rises to another level

Hong Kong continues to expand its global healthcare footprint as the world’s second-largest biotech fundraising hub. As Hong Kong’s flagship innovation and technology ecosystem, HKSTP is home to more than 300 life and health technology companies and helps innovators turn pioneering ideas into real-world impact. Its ecosystem connects capital, talent, infrastructure and market access across the biotech innovation journey.

Recommended Articles